Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation develops and commercializes PET and PET-CT molecular imaging systems and related clinical services for nuclear medicine providers in North America. The company specializes in cardiac Positron Emission Tomography applications, including PET-CT scanners and practice support for cardiovascular diagnostic providers.
Company news commonly covers scanner sales and multi-unit orders, long-term service agreements, the NeuSight PET-CT 64-slice system, industry partnerships, product development, regulatory activities, capital raises, and its transition to SEC reporting status. Updates also describe how Positron combines imaging hardware, software, clinical support, technical support, and training services for nuclear cardiology and broader molecular imaging practices.
Positron Corporation (OTC: POSC) announced on February 17, 2026 the sale of four (4) PET-CT 64-slice scanners plus associated long-term services agreements to three nuclear cardiology practices led by nationally recognized physicians.
Products highlight a 72cm wide-bore gantry, high-sensitivity detectors for reduced radiation, a compact footprint, and advanced data acquisition for cardiac and oncology imaging.
Positron Corporation (OTC: POSC) announced a $2.0 million capital raise on Dec. 30, 2025, issuing 1,333,333 shares in exchange for the proceeds.
The company said the funds will be used to accelerate commercial expansion, advance product development and regulatory activities, pursue new markets, and support increased placements of cardiac PET and PET-CT systems.
Management described the financing as strengthening the balance sheet to support near-term growth initiatives and longer-term opportunities in new products, markets, clinical services, and technology development.
Positron Corporation (OTC: POSC) announced on November 17, 2025 that it has become an SEC reporting company by filing a Form 10 containing required financial statements and disclosures.
The company will now file quarterly, annual, and current reports under the Securities Exchange Act of 1934, enhancing financial transparency, strengthening corporate governance, and positioning Positron to pursue an uplisting to a senior exchange. Management said the change supports broader institutional visibility and access to capital as Positron commercializes its PET-CT technologies, including a new 4D PET-CT system, and leverages an exclusive North American partnership with Neusoft Medical Systems.
Positron Corporation (OTC: POSC), a molecular imaging technology company specializing in PET and PET-CT systems, has announced a strategic partnership with MedAxiom, a leading cardiovascular performance solutions provider.
The partnership connects Positron with MedAxiom's extensive network of cardiovascular organizations, physicians, and thought leaders. This collaboration will provide Positron with market intelligence, clinical insights, and collaboration opportunities to support broader adoption of PET-CT technology in cardiovascular care.
MedAxiom's Executive VP Joe Sasson highlighted the rapid growth of Cardiac PET in transforming cardiovascular care, while Positron's President Adel Abdullah emphasized the partnership's potential to expand their user base and accelerate adoption of their imaging solutions.
Positron Corporation (OTC: POSC) has been awarded the Innovation Award in the PET-CT Imaging category at the 2025 Medical Device Network Excellence Awards. The company's PET-CT 64 Slice system stands out as the most cost-effective PET-CT system in the US, making advanced hybrid imaging more accessible to smaller clinics and community hospitals.
The system offers significant advantages including enhanced workflow efficiency with capability to perform up to 20+ exams daily, flexible rental packages, and comprehensive clinical applications across cardiac, oncology, and neurology imaging. Positron plans to launch its advanced Affinity 4D PET-CT system in Q4 2025, featuring LYSO crystal technology, AI-enhanced motion monitoring, and improved dose reduction techniques.
Positron Corporation (OTC: POSC), a molecular imaging technology leader, has announced two strategic corporate developments. The company has established a new corporate headquarters in the Buffalo-Niagara Falls region under a long-term lease, which will serve as their corporate operations hub, product showroom, and testing center.
Additionally, Positron's Board of Directors has approved the company's redomiciling from Texas to Delaware. This move aims to enhance corporate governance and legal framework as the company prepares to file a Form 10 registration statement with the SEC to become a fully reporting public company.
Positron Corporation (OTC: POSC) has secured a significant sale of four PET-CT 64-slice scanners to a leading nuclear cardiology group. The company's next-generation imaging systems feature a 72 cm wide-bore gantry, high-sensitivity detectors with reduced radiation exposure, and the smallest footprint in its class.
The PET-CT scanners deliver high-resolution anatomic and functional imaging for both cardiac and oncology applications, offering enhanced diagnostic capabilities from myocardial perfusion to tumor detection. The deal highlights growing market acceptance of Positron's advanced imaging technology and comprehensive support services.
Positron Corporation (OTC: POSC) has announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist. The NeuSight PET-CT scanner features a 72 cm gantry and high-sensitivity acquisition technology that reduces radiation exposure. The system, which has the smallest footprint in its class, is designed for both cardiology and oncology applications, offering anatomic and functional imaging capabilities.
The scanner supports various studies, including cardiac, tumor, and neurological imaging. According to President Adel Abdullah, this sale to a key opinion leader (KOL) of a larger medical group represents a potential gateway to broader organizational opportunities as Positron expands into the western U.S. market.
Positron (OTC: POSC) has announced the sale of four PET-CT scanners to a prominent cardiovascular diagnostics provider. The company's molecular imaging systems feature a 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining compact design.
The PET-CT systems are engineered for both cardiology and oncology applications, offering advanced data acquisition capabilities for faster and more precise scans. Key features include the smallest footprint in their class, versatility for cardiac and tumor imaging, and brain studies capabilities.
According to Adel Abdullah, President of Positron, this sale reflects growing demand for cardiac PET imaging. The company aims to make PET technology more accessible through cost-effective solutions and comprehensive support services.
Positron (POSC) has secured an $8 million equity investment through the sale of 8 million common shares to two strategic investors. The capital will fund the company's expansion in the PET-CT imaging market, particularly in nuclear cardiology and oncology.
The funding will support multiple strategic initiatives, including:
- Enhanced sales and marketing efforts
- Expansion of sales personnel
- Product development and offerings
- Strengthening industry partnerships
- Market expansion in North America and Europe
The company plans to use this capital to resume SEC filings and pursue an uplisting to a senior stock exchange. According to President Adel Abdullah, this investment positions Positron to capitalize on increasing PET-CT imaging adoption and develop a competitive edge in the marketplace.